Is hepatitis C virus eradication around the corner only 25 years after its discovery?

International Journal of Antimicrobial Agents

Volumn 45, Issue 2, 2015, Pages 111-112

  Ippolito, Giuseppe ^a   Capobianchi, Maria Rosaria ^a   Lanini, Simone ^a   Antonelli, Guido ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiviral therapy; HCV; Hepatitis C virus

Indexed keywords

INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NOTE; PRACTICE GUIDELINE; TREATMENT PLANNING; DRUG EFFECTS; ECONOMICS; HEPACIVIRUS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG COSTS; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 84921492544     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.09.001     Document Type: Note

References (14)

1. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J Hepatol 2009;51:939-48.
2. Ali A, Zein NN. Hepatitis C infection: a systemic disease with extrahepatic manifestations. Cleve Clin J Med 2005;72, 1005-8, 1010-4, 1016.
3. Samuel DG, Rees IW. Extrahepatic manifestations of hepatitis C virus (HCV). Frontline Gastroenterol 2013;4:249-54.
4. Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev 2014;2:CD005441.
5. Ippolito G, Antonelli G, Capobianchi MR, Lanini S. HCV treatment revolution: needs for close monitoring. Clin Microbiol Infect 2014, http://dx.doi.org/10.1111/1469-0691.12693. May 28 [Epub ahead of print].
6. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998;76(Suppl. 2):22-5.
7. Valdiserri R, Khalsa J, Dan C, Holmberg S, Zibbell J, Holtzman D, et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 2014;104:816-21.
8. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005;40(Suppl. 5):S367-72.
9. Lanini S, Abbate I, Puro V, Soscia F, Albertoni F, Battisti W, et al. Molecular epidemiology of a hepatitis C virus epidemic in a haemodialysis unit: outbreak investigation and infection outcome. BMC Infect Dis 2010;10:257.
10. Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis 2014;16:1-16.
11. Antonucci G, Goletti D, Lanini S, Girardi E, Loiacono O. HIV/HCV co-infection: putting the pieces of the puzzle together. Cell Death Differ 2003;10(Suppl. 1):S25-6.
12. American Association for the Study of the Liver Diseases (AASLD); Infectious Diseases Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/ [accessed 18.06.14].
13. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. http://www.easl.eu/-newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014 [accessed 18.06.14].
14. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO; April 2014. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ [accessed 18.06.14].